- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03339635
Short-term Testosterone Replacement in Testicular Cancer Survivors
Short-term Testosterone Replacement in Testicular Cancer Survivors to Treat Overweight and Improve Cardiometabolic Risk: A Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rationale: Testicular cancer (TC) survivors have an increased risk of hypogonadism (decreased testosterone and/or increased luteinizing hormone levels) and cardiovascular disease (CVD). Metabolic syndrome develops early after chemotherapy in 20-30% of long-term TC survivors and is associated with an increased risk of atherosclerotic disease in the general population. TC survivors who develop the metabolic syndrome have a higher body mass index (BMI) pretreatment, a larger BMI increase during follow-up, and lower total testosterone levels than patients without the metabolic syndrome. Testosterone replacement therapy as a short-term intervention during a limited time period may be an important strategy to reduce body weight and fat mass, restore cardiometabolic balance, and decrease the prevalence of the metabolic syndrome in TC survivors.
Objective: to assess the effects of testosterone replacement therapy on fat mass and other components of the metabolic syndrome.
Study design: randomized double-blind placebo controlled intervention study, followed by an open-label treatment phase. Results of this pilot study will be used to design a multicenter randomized controlled study in a large group of TC survivors
Study population: 40 TC patients, aged 18-55 years, at least 12 months after completion of curative treatment with unilateral orchidectomy and platinum-based chemotherapy, and having a fasting total testosterone level ≤12 nmol/l and a BMI ≥25 kg/m2.
Intervention: Patients will be randomized to treatment with transdermal testosterone gel (Androgel) or placebo gel once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants. The treatment dose will be 50 mg daily, adjusted to 25 mg in case of increased testosterone concentrations (average of 2 measurements >25 nmol/L) or signs of overdosing. Patients will be stratified according to testosterone level (8-12 nmol/L versus <8 nmol/L) and BMI (25-30 kg/m2 versus 30-35 kg/m2).
Main study parameters/endpoints: Primary endpoint is the change in fat mass as measured by Dual-Energy X-ray Absorption (DEXA) scan after 20 weeks of Androgel compared to placebo. Secondary endpoints are changes in fat mass between 20 and 40 weeks, and changes in abdominal visceral fat, BMI, adipocytokines, metabolic syndrome parameters, bone mass density, semen quality, sexual function, and quality of life between Androgel and placebo-treated patients.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The study will provide an answer to the question whether testosterone replacement therapy as a short-term intervention has significant effects on obesity and fat metabolism and may, thus, reduce the prevalence of the metabolic syndrome in this population of young men with excellent long-term cancer-related prognosis, but an increased CVD risk. At various time points during the intervention, patients will be subjected to history taking and physical examination. Furthermore, blood will be drawn to: measure hormone levels, adipocytokines, lipids, glucose, insulin, and bone markers; to extract DNA for determination of gene polymorphisms; and to measure hematocrit and PSA as safety parameters. Semen analysis and a full body DEXA scan will be performed at 0, 20 and 40 weeks only. Patients will be asked to fill out questionnaires regarding quality of life, sexual health, and androgen deficiency symptoms at various time points during the intervention.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Janine Nuver, MD, PhD
- Phone Number: +31 50 3612821
- Email: j.nuver@umcg.nl
Study Locations
-
-
-
Groningen, Netherlands, 9713 GZ
- University Medical Center Groningen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- patients with metastatic testicular cancer after unilateral orchidectomy and chemotherapy, at least 12 months after completion of last treatment and without evidence of disease. Combination chemotherapy should have contained a platinum compound, either cisplatin or carboplatin. In TC survivors, testosterone levels are routinely measured in blood during follow-up once every two years.
- Patients are eligible for screening if they are between 18 and 55 years of age
- have a documented low or low-normal total testosterone level ≤14 nmol/L, as measured during any of the follow-up visits, irrespective of signs and symptoms of androgen deficiency.
Eligible for actual study participation and randomization between Androgel and placebo will be:
- survivors of TC not using testosterone supplements, having biochemical evidence of hypogonadism (defined as a serum total testosterone concentration ≤ 12 nmol/L (345 ng/dL) measured after an overnight fast between 8:00 and 10:00 AM), and being overweight (as defined by a BMI ≥ 25 and <35 kg/m2).
- Patients should be able to understand and abide to the study protocol and sign written informed consent.
Exclusion Criteria:
- patients with a history of extragonadal testicular cancer
- patients planning to father children within the next 12 months
- patients taking corticosteroids or hormone replacement other than testosterone within 3 months of randomization
- patients taking medication with any antiandrogenic effects (e.g. spironolactone)
- patients with signs or history of hormone-dependent cancer (prostate or breast cancer)
- patients with severe lower urinary tract symptoms (as defined by International Prostate Symptom Score >19)
- patients with a history of coronary artery disease (angina pectoris, myocardial infarction) or heart failure
- patients with hematocrit >50%
- patients with untreated severe obstructive sleep apnea
- patients with uncontrolled hypertension
- patients with a BMI > 35 kg/m2
- patients with a history of epilepsy
- patients with debilitating psychiatric illness or inability to understand the study protocol, according to the opinion of the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Testosterone gel
Patients will be randomized to treatment with transdermal testosterone gel (Androgel) once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
|
Patients will be randomized to treatment with transdermal testosterone gel (Androgel) once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
Other Names:
|
Placebo Comparator: Placebo gel
Patients will be randomized to treatment with placebo gel once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
|
Patients will be randomized to treatment with transdermal testosterone gel (Androgel) once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
Other Names:
Patients will be randomized to treatment with transdermal placebo gel once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
percent change in fat mass as measured using using full body dual X-ray absorptiometry
Time Frame: 20 weeks of treatment
|
To assess the effects of 20 weeks of treatment with testosterone gel on fat mass as measured using full body dual X-ray absorptiometry (DEXA scan).
|
20 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of treatment with testosterone gel
Time Frame: 20 and 40 weeks of treatment
|
To assess the effects of 20 and 40 weeks of treatment with testosterone gel on obesity
|
20 and 40 weeks of treatment
|
Effect of treatment with testosterone gel
Time Frame: 20 and 40 weeks of treatment
|
To assess the effects of 20 and 40 weeks of treatment with testosterone gel on signs and symptoms of hypogonadism
|
20 and 40 weeks of treatment
|
Collaborators and Investigators
Investigators
- Principal Investigator: Janine Nuver, MD, PhD, University Medical Center Groningen
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Genital Neoplasms, Male
- Testicular Diseases
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Testicular Neoplasms
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Androgens
- Anabolic Agents
- Testosterone
- Methyltestosterone
- Testosterone undecanoate
- Testosterone enanthate
- Testosterone 17 beta-cypionate
Other Study ID Numbers
- 201600107
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Testicular Cancer
-
Haukeland University HospitalKarolinska University Hospital; Oslo University Hospital; University Hospital... and other collaboratorsRecruitingSeminoma | Testicular Germ Cell Cancer | Non-Seminoma Testicular Cancer | Stage I Testicular Cancer | Stage II Testicular Cancer | Stage III Testicular Cancer | Stage IV Testicular Cancer | Relapse Testicular CancerNorway, Sweden
-
University Medical Center GroningenDutch Cancer SocietyCompletedNon-seminomatous Testicular CancerNetherlands
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)RecruitingSeminoma | Germ Cell Tumor | Metachronous Malignant Neoplasm | Stage I Testicular Cancer AJCC v8 | Stage IA Testicular Cancer AJCC v8 | Stage IB Testicular Cancer AJCC v8 | Stage IS Testicular Cancer AJCC v8Canada, United States, Guam
-
National Cancer Institute, SlovakiaCompletedTesticular CancerSlovakia
-
University of California, IrvineMemorial Sloan Kettering Cancer CenterUnknown
-
University of Texas Southwestern Medical CenterActive, not recruitingTesticular Germ Cell Tumor | Testicular Neoplasms | Testicular Diseases | Testis Cancer | Testicular Cancer | Germ Cell Tumor | Testicular Yolk Sac Tumor | Testicular Choriocarcinoma | Germ Cell Tumor of Testis | Germ Cell Tumor, Testicular, Childhood | Germ Cell Cancer Metastatic | Germ Cell Neoplasm of Retroperitoneum and other conditionsUnited States
-
University Medical Center GroningenDutch Cancer SocietyRecruitingTesticular CancerNetherlands
-
Radboud University Medical CenterCompletedTesticular CancerNetherlands
-
Centre Hospitalier Universitaire de NiceTerminatedTesticular CancerFrance
-
University Medical Center GroningenCompletedBreast Cancer | Testicular CancerNetherlands
Clinical Trials on Androgel (Testosterone gel)
-
AbbottFoveaCompletedHypogonadismCanada, Croatia, Germany, Kuwait, Romania, Russian Federation, Saudi Arabia, Slovenia, United Arab Emirates
-
SELARL du Dr Jacques BUVATBayerCompletedErectile Dysfunction | HypogonadismFrance
-
Clarus Therapeutics, Inc.CompletedMale HypogonadismUnited States, Germany
-
Hanoi Medical UniversityNational Hospital of Obstetrics and GynecologyCompleted
-
Canisius-Wilhelmina HospitalBesins HealthcareRecruitingProstatic Neoplasms | Hypogonadism | Testosterone DeficiencyNetherlands
-
University of PennsylvaniaEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
-
University of Colorado, DenverNational Institute of Neurological Disorders and Stroke (NINDS); Children's... and other collaboratorsCompletedKlinefelter Syndrome | XXY SyndromeUnited States
-
Craig HospitalUniversity of Colorado, DenverCompletedBrain Injury | Trauma | Endocrine DysfunctionUnited States
-
University of WashingtonNational Institutes of Health (NIH); National Institute on Aging (NIA)CompletedHealthyUnited States
-
McGuire Research InstituteSolvay PharmaceuticalsCompletedMetabolic Syndrome | HypogonadismUnited States